Mi az ára Coeptis Therapeutics Holdings, Inc. (COEP)

Coeptis Therapeutics Holdings, Inc. (COEP) ára $4.81

Mi a Coeptis Therapeutics Holdings, Inc. (COEP piaci tőkésítése)

Coeptis Therapeutics Holdings, Inc. piaci tőkésítése (COEP) $29.01M

Coeptis Therapeutics Holdings, Inc. (COEP) Árfolyamtörténet

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Év	Teljesítmény
2026 (TTM)	-14.55%
2025	310.00%
2024	-80.37%
2023	-39.69%
2022	-84.27%
2021	-1.07%
2020	0.00%

Év

Teljesítmény

2026 (TTM)

-14.55%

2025

310.00%

2024

-80.37%

2023

-39.69%

2022

-84.27%

2021

-1.07%

2020

0.00%

Vállalat	Részvényár	Változás 1év%	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$552.07	39.99%	US
Moderna, Inc. MRNA.US	$168.77	527.63%	US
Argenx SE ARGX.US	$1.03K	56.22%	NL
CSL Limited CSL.AX	$122.91	-13.46%	AU
Lonza Group AG LONN.SW	$753.28	5.84%	CH

Vállalat

Részvényár

Változás 1év%

Ország